Literature DB >> 7643357

Stepwise or couple antenatal carrier screening for cystic fibrosis?: women's preferences and willingness to pay.

Z Miedzybrodzka1, J Semper, P Shackley, M Abdalla, C Donaldson.   

Abstract

Several antenatal cystic fibrosis carrier screening trials have offered women testing by either the stepwise or the couple method. In this study, both approaches were described to women attending an antenatal clinic, who were then asked which method they preferred. An estimate of the value to women of each type of test was also ascertained using a "willingness to pay" (WTP) method. Of 450 women, 279 (62%) preferred stepwise screening, 117 (26%) preferred couple screening, and 54 (12%) had no preference. Mean WTP for stepwise screening was 19 pounds (95% CI 17.50 pounds-20.50 pounds), and that for couple screening was 18 pounds (95% CI 16.50 pounds-19.50 pounds). The majority of women preferred stepwise screening although the average WTP for each method was similar.

Entities:  

Mesh:

Year:  1995        PMID: 7643357      PMCID: PMC1050376          DOI: 10.1136/jmg.32.4.282

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  6 in total

1.  Couple screening for cystic fibrosis.

Authors:  N J Wald
Journal:  Lancet       Date:  1991-11-23       Impact factor: 79.321

2.  Willingness-to-pay as a measure of benefits. Relevant questions in the context of public decisionmaking about health care programs.

Authors:  A Gafni
Journal:  Med Care       Date:  1991-12       Impact factor: 2.983

3.  Counting the benefits of screening: a pilot study of willingness to pay for cystic fibrosis carrier screening.

Authors:  Z Miedzybrodzka; P Shackley; C Donaldson; M Abdalla
Journal:  J Med Screen       Date:  1994-04       Impact factor: 2.136

4.  Antenatal screening for carriers of cystic fibrosis: randomised trial of stepwise v couple screening.

Authors:  Z H Miedzybrodzka; M H Hall; J Mollison; A Templeton; I T Russell; J C Dean; K F Kelly; T M Marteau; N E Haites
Journal:  BMJ       Date:  1995-02-11

5.  Prenatal screening for cystic fibrosis.

Authors:  M E Mennie; A Gilfillan; M Compton; L Curtis; W A Liston; I Pullen; D A Whyte; D J Brock
Journal:  Lancet       Date:  1992-07-25       Impact factor: 79.321

6.  Antenatal screening for cystic fibrosis: a trial of the couple model.

Authors:  J Livingstone; R A Axton; A Gilfillan; M Mennie; M Compton; W A Liston; A A Calder; A J Gordon; D J Brock
Journal:  BMJ       Date:  1994-06-04
  6 in total
  7 in total

1.  Assessing community values in health care: is the 'willingness to pay' method feasible?

Authors:  C Donaldson; S Farrar; T Mapp; A Walker; S Macphee
Journal:  Health Care Anal       Date:  1997-03

2.  Genetic testing in the European Union: does economic evaluation matter?

Authors:  Fernando Antoñanzas; R Rodríguez-Ibeas; M F Hutter; R Lorente; C Juárez; M Pinillos
Journal:  Eur J Health Econ       Date:  2011-05-20

3.  Update and Review: Cystic Fibrosis.

Authors:  T Brown; E L Schwind
Journal:  J Genet Couns       Date:  1999-06       Impact factor: 2.537

4.  Cost effectiveness of antenatal screening for cystic fibrosis.

Authors:  H S Cuckle; G A Richardson; T A Sheldon; P Quirke
Journal:  BMJ       Date:  1995-12-02

5.  Assessing the willingness of parents to pay for reducing postoperative emesis in children.

Authors:  L Diez
Journal:  Pharmacoeconomics       Date:  1998-05       Impact factor: 4.981

6.  Prenatal screening for cystic fibrosis carriers: an economic evaluation.

Authors:  P T Rowley; S Loader; R M Kaplan
Journal:  Am J Hum Genet       Date:  1998-10       Impact factor: 11.025

7.  Current attitudes and preconceptions towards expanded carrier screening in the Eastern Chinese reproductive-aged population.

Authors:  Fang Zhang; Jianxin Tan; Binbin Shao; Tao Jiang; Ran Zhou; Yan Wang; Jingjing Zhang; Fengchang Qiao; Xiuqing Ji; Ya Wang; Ping Hu; Zhengfeng Xu
Journal:  J Assist Reprod Genet       Date:  2021-01-06       Impact factor: 3.412

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.